Her consultant told her about the Oncotype DX test and she wasted no time in moving forward with the test.
Ann, a grandmother from Gloucestershire, UK, was diagnosed with early stage breast cancer in December 2011, just before Christmas. The operation to remove her tumor took place in January, and following this her consultant informed her that based on data from other women of her age and stage of disease advancement, she was a 'borderline' case for chemotherapy as her estimated chance of responding was 3-4%.
“I found it impossible to make an informed decision based on historical data.”
Ann was uneasy with basing her decision on whether to proceed with chemotherapy upon data from other women, "I found it impossible to make an informed decision based on historical data. My illness was about my body, my cancer - not about ladies who had gone before me," and before putting herself through grueling chemotherapy she wanted to know how beneficial it would be. It was at this point that her consultant told her about the Oncotype DX test and she wasted no time in moving forward with the test. In March 2012, Ann received her results which showed that she had a low Recurrence Score result and was unlikely to benefit from chemotherapy. "I believe anyone facing breast cancer should be given the facts about Oncotype DX – making an informed treatment decision is a right all women should have."
To wind down from her busy job in technical sales, Ann enjoys sewing, quilting, and getting lost in a good book. Her two children and young grandchildren also regularly come over for Sunday lunch, followed by a long walk in the countryside.
Back to Search Results